Funding
RAS and JFT are recipients of a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1093017). RAS is also supported by an NHMRC Practitioner Fellowship (APP1141295) and a Melanoma Research Alliance (MRA) Team Science Award (Award No. 700455—https://doi.org/10.48050/pc.gr.91584). DJC, SNL, TA, JRS, and RPMS are supported by Melanoma Institute Australia.
Author information
Authors and Affiliations
Contributions
AKL, DJC, and RPMS were involved in the initial concept of the article. AKL, DJC, SNL, TA, RAS, JFT, and RPMS were involved in data analysis and interpretation and initial drafting of the article. SNL and TA were involved in statistical analysis. All authors were involved in the study design, data acquisition, critical revision of the article and final approval of the manuscript. AKL and DJC are considered joint principal investigators and co-first authors, having contributed equally to the work. RPMS and JT are considered co-senior authors, having contributed equally to the work.
Corresponding author
Ethics declarations
Disclosures
RAS has received fees for professional services from Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline, F. Hoffmann-La Roche. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, travel support from GSK and Provectus Inc and support for conference attendance from Novartis. RPMS has received honoraria for advisory board participation from MSD, Qbiotics and Novartis and speaking honoraria from BMS and Novartis. AKL, DJC, SNL, TA, SC, OEN, KS, AS, and JRS have no conflicts of interest to declare.
Additional information
This work was presented as an ePoster at the World Congress of Melanoma, Rome, April 2021.
Rights and permissions
About this article
Cite this article
Lawless, A.K., Coker, D.J., Lo, S.N. et al. ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases. Ann Surg Oncol 29, 7031–7032 (2022). https://doi.org/10.1245/s10434-022-12266-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12266-w